Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial
Treatment with 300 mg (orally) of sarpogrelate demonstrated statistically significant improvements in all domains and for the summary score of the PAQ at 24 weeks, it gave good results in terms of safety. Sarpogrelate may be helpful in reducing symptoms related to PAD.
Authors
- Ung Bae Jeon
- Soo Kyung Lim (ORCID: https://orcid.org/0000-0002-4137-1671)
- Jae Hyoung Park (ORCID: https://orcid.org/0000-0001-8434-0157)
- Jong Chul Won (ORCID: https://orcid.org/0000-0002-2219-4083)
- Hee-Tae Kim (ORCID: https://orcid.org/0000-0002-7722-4841)
- Ho-Seung Jeong (ORCID: https://orcid.org/0000-0001-7297-5534)
- Tae-Jin Song (ORCID: https://orcid.org/0000-0002-6356-0676)
- Kyung Wan Min
- K.H. Lee
- Keun Yong Park
Institutions
- Ewha Womans University (KR)
- Korea University Medical Center (KR)
- Soonchunhyang University Hospital Seoul (KR)
- Seoul National University Bundang Hospital (KR)
- Gachon University Gil Medical Center (KR)
- Konyang University Hospital (KR)
- Inje University Sanggye Paik Hospital (KR)
- Hanyang University Seoul Hospital (KR)
- Chungbuk National University Hospital (KR)
- Eulji Medical Center (KR)
Publication Details
- Journal
- Current Vascular Pharmacology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.2174/0115701611285172241015074050
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00